MegaPro Biomedical Co., Ltd (TPEX:6827)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.70
-0.20 (-1.55%)
Apr 29, 2026, 1:56 PM CST
35.54%
Market Cap 834.90M
Revenue n/a
Net Income n/a
Shares Out 64.72M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 237,907
Average Volume 287,405
Open 12.55
Previous Close 12.90
Day's Range 12.05 - 12.95
52-Week Range 8.80 - 20.10
Beta 0.68
RSI 57.69
Earnings Date n/a

About MegaPro Biomedical

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6827
Full Company Profile

News

There is no news available yet.